US 11,833,169 B2
Oligosaccharide compound for inhibiting intrinsic coagulation factor X-enzyme complex, and preparation method therefor and uses thereof
Jinhua Zhao, Kunming (CN); Zhenguo Li, Changsha (CN); Na Gao, Kunming (CN); Mingyi Wu, Kunming (CN); Yanming Chen, Mudanjiang (CN); Longyan Zhao, Kunming (CN); Yongsheng Wu, Mudanjiang (CN); Zi Li, Kunming (CN); Chuang Xiao, Kunming (CN); Shunliang Zheng, Mudanjiang (CN); Zhiyuan Nan, Mudanjiang (CN); Jianbo Zhou, Mudanjiang (CN); Jianping Xu, Kunming (CN); Lutan Zhou, Kunming (CN); Yafang Guo, Mudanjiang (CN); Hongbo Qin, Kunming (CN); and Jikai Liu, Kunming (CN)
Assigned to MUDANJIANG YOUBO PHARMACEUTICAL CO., LTD., Mudanjiang (CN); and JIUZHITANG CO., LTD., Changsha (CN)
Appl. No. 16/476,720
Filed by Jiuzhitang Co., Ltd., Changsha (CN); and Mudanjiang YouBo Pharmaceutical Co., Ltd., Mudanjiang (CN)
PCT Filed Jan. 10, 2017, PCT No. PCT/CN2017/070716
§ 371(c)(1), (2) Date Oct. 8, 2019,
PCT Pub. No. WO2018/129647, PCT Pub. Date Jul. 19, 2018.
Prior Publication US 2020/0254003 A1, Aug. 13, 2020
Int. Cl. A61K 31/727 (2006.01); A61P 7/02 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/727 (2013.01) [A61K 9/0019 (2013.01); A61P 7/02 (2018.01)] 10 Claims
 
1. An oligosaccharide compound or a pharmaceutically acceptable salt thereof, characterized in that, the oligosaccharide compound has antithrombotic activity, and has a general structure represented by Formula (I):

OG Complex Work Unit Chemistry
in the formula,
n is a number from 0 to 8;
R1, R2, R3, R4, and R5 are independently selected from —H or —SO3H;
R6 is selected from —H, a substituted or unsubstituted C1-C6 hydrocarbon group or a C7-C12 aryl group;
R7 is selected from —H, —SO3H, C2-C5 acyl;
R8 is Formula (II), Formula (III) or Formula (IV):

OG Complex Work Unit Chemistry
in Formula(II), Formula (III) and Formula(IV),
R1, R2, R3, R4, R5, R6 and R7 are defined as above;
R9 and R10 are independently selected from —H, a substituted or unsubstituted C1-C6 hydrocarbon group or a C7-C12 aryl group; and
R11 is selected from —NHR12, —OR13, wherein R12 and R13 are independently selected from —H, a substituted or unsubstituted C1-C6 hydrocarbon group, or a C7-C12 aryl group;
wherein, the compound is a purified oligosaccharide compound prepared by β-elimination depolymerization and terminal reduction with a reducing agent during the β-elimination or β-elimination depolymerization and a peeling reaction with a strong base during the β-elimination, followed by isolation and purification.